溃疡性结肠炎患者暴露于肿瘤坏死因子抑制剂后生物制剂和小分子药物作为二线治疗的疗效:一项倾向匹配队列研究
本研究利用TriNetX多机构数据库开展回顾性队列研究,比较托法替布、维得利珠单抗和乌司奴单抗在既往暴露于TNFi的UC患者中的疗效。经倾向评分匹配后,托法替布组结肠切除风险高于维得利珠单抗组和乌司奴单抗组;维得利珠单抗组复合结局风险高于乌司奴单抗组。结论提示乌司奴单抗可能为优选二线治疗。
要点
- 托法替布组结肠切除风险高于维得利珠单抗组(aOR 2.69)和乌司奴单抗组(aOR 2.63)。
- 维得利珠单抗组复合结局风险高于乌司奴单抗组(aOR 1.67)。
- 乌司奴单抗可能是既往暴露于TNFi的UC患者优选的二线治疗。
核心结论
- 乌司奴单抗可能是既往暴露于TNFi的UC患者优于托法替布和维得利珠单抗的优选二线治疗。
研究设计与样本
- 利用TriNetX多机构数据库开展的回顾性队列研究,纳入2141例既往暴露于TNFi的UC患者。
- 比较托法替布、维得利珠单抗和乌司奴单抗的疗效,主要结局为2年内静脉激素或结肠切除的复合结局。
- 对人口学、疾病范围、平均血红蛋白、C反应蛋白、白蛋白、钙卫蛋白、既往IBD用药和激素使用进行一对一倾向评分匹配。
主要发现
- 2141例患者中,348例(16.2%)换用托法替布,716例(33.4%)换用乌司奴单抗,1077例(50.3%)换用维得利珠单抗。
- 倾向匹配后,托法替布组与维得利珠单抗组复合结局无差异(aOR 0.77,95% CI 0.55-1.07),但托法替布组结肠切除风险更高(aOR 2.69,95% CI 1.31-5.50)。
- 托法替布组与乌司奴单抗组复合结局无差异(aOR 1.29,95% CI 0.89-1.86),但托法替布组结肠切除风险更高(aOR 2.63,95% CI 1.24-5.58)。
- 维得利珠单抗组复合结局风险高于乌司奴单抗组(aOR 1.67,95% CI 1.29-2.16)。
临床怎么用
- 作者认为,乌司奴单抗可能是既往暴露于TNFi的UC患者优选的二线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is limited real-world data on comparative effectiveness of different biologic or small molecule agents as second-line therapies in patients with ulcerative colitis (UC) with prior exposure to a tumour necrosis factor inhibitor (TNFi). METHODS: We conducted a retrospective cohort study using TriNetX, a multi-institutional database to assess the efficacy of tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis (UC) with prior exposure to a TNFi. Failure of medical therapy was defined as a composite outcome of intravenous steroids or colectomy within 2 years. One-to-one propensity score matching was performed for demographics, disease extent, mean haemoglobin, C-reactive protein, albumin and calprotectin, prior IBD medications and steroid use between cohorts. RESULTS: Among 2141 patients with UC and prior exposure to TNFi, 348 (16.2%), 716 (33.4%) and 1077 (50.3%) were switched to tofacitinib, ustekinumab and vedolizumab, respectively. After propensity-score matching, there was no difference in the composite outcome (aOR: 0.77, 95% CI: 0.55-1.07) but higher risk of colectomy (aOR: 2.69, 95% CI: 1.31-5.50) in the tofacitinib cohort than the vedolizumab cohort. There was no difference in the risk of composite outcome (aOR: 1.29, 95% CI: 0.89-1.86) but higher risk of colectomy (aOR: 2.63, 95% CI: 1.24-5.58) in the tofacitinib cohort than the ustekinumab cohort. The vedolizumab cohort had a higher risk of composite outcome (aOR: 1.67, 95% CI: 1.29-2.16) than the ustekinumab cohort. CONCLUSION: Ustekinumab might be the preferred second-line therapy over tofacitinib and vedolizumab in patients with UC that were previously exposed to a TNFi.
引用
- Kochhar GS, Desai A, Farraye FA, et al. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study. Aliment Pharmacol Ther. 2023. PMID: 37300328. doi:10.1111/apt.17570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。